New Psoriasis Drug Approved in U.S., But with a Warning — Physician’s First Watch

Medical News |
February 17, 2017

New Psoriasis Drug Approved in U.S., But with a Warning

By Kelly Young

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The FDA has approved brodalumab (Siliq) to treat moderate-to-severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy and have not responded to other systemic treatments.

In three randomized trials of 4400 patients, brodalumab users saw better skin clearance than placebo users.

The injectable drug, which targets the interleukin-17A receptor, will come with a boxed warning about a possible risk for suicidal ideation. In clinical trials, patients with a history of suicidality or depression had a higher rate of suicidal ideation and behavior than those without similar histories. So far, there is no proven causal link between the drug and suicidality.

Other possible risks include the potential for serious infections or autoimmune or allergic conditions. The drug is contraindicated in patients with Crohn disease or active tuberculosis infection. Before treatment with brodalumab, patients should be evaluated for TB. Patients taking the drug should not be immunized with live vaccines

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.